Inhibitor of the p110 isoform of PI3 kinase
Home > PRODUCTS > Biochemicals > Inhibitor of the p110 isoform of PI3 kinase

Academic Discounts 2019

Newsletter Subscription

Stay updated with our new products and services. You can unsubscribe at any time.

Inhibitor of the p110 isoform of PI3 kinase

2-[(6-Amino-9H-purin-9-yl)methyl]-5-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone (IC87114)
selective inhibitor of the p110δ isoform of PI3 kinase

OTAVAchemicals Catalogue Number: 7070707046
CAS Registry Number: 371242-69-2
Purity: 95%+ (HPLC)

Ref.: Billottet et al. A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene (2006), 25, 6648-6659

Abstract: Current therapy for acute myeloid leukemia (AML) is suboptimal with a high incidence of relapse. There is strong evidence that constitutive phosphoinositide 3-kinase (PI3K) activity plays a significant role in the pathophysiol. of AML. PI3K products are derived from the activity of a no. of PI3K catalytic isoforms (class I, II and III) but the relative contribution of these enzymes in AML remains unknown. As nonisoform-selective inhibitors of PI3K such as LY294002 may produce unwanted toxicity to normal tissues, the authors have investigated the role of the leukocyte-restricted p110δ PI3K isoform in 14 cases of AML. The isoform p110δ was detected in all cases whereas the expression levels of the other class I PI3Ks varied more widely, and were often undetectable. The p110δ-selective compd. IC87114 inhibited constitutive phosphorylation of the PI3K target Akt/PKB and reduced cell no. to a mean of 66±5% (range 14-88%). In eight cases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing viable cell no., and was associated with a reduction in constitutive NF-κB activity. IC87114 did not have direct adverse effects or enhance the activity of VP16 on the proliferation and survival of normal hemopoietic progenitors. Overall, our results identify the p110δ isoform as a potential therapeutic target in AML and support a clinical approach to use isoform-selective over broad-spectrum PI3K inhibitors.